Gyre Therapeutics, Inc. GYRE EBITDA margin

EBITDA margin at other companies

Eli LillyLLY

44.8%+9.6pp

Madrigal Pharmaceuticals, Inc.MDGL

-25%-9.2pp

Theravance BiopharmaTBPH

-2.5%-1.2pp

Rigel PharmaceuticalsRIGL

42.4%+19.5pp

Zevra Therapeutics, Inc.ZVRA

65.5%+37.8pp

LQD

Liquidia CorporationLQDA

-152.5%-66.9pp

FAQ

What is Gyre Therapeutics, Inc.'s EBITDA margin?

Gyre Therapeutics, Inc. (GYRE) reported EBITDA margin of -11.4% in Q2 2026.

How has Gyre Therapeutics, Inc.'s EBITDA margin changed year-over-year?

Gyre Therapeutics, Inc.'s EBITDA margin decreased by 262.1% year-over-year, from 7% to -11.4%.

What is the long-term trend for Gyre Therapeutics, Inc.'s EBITDA margin?

Over 4 years (2020 to 2025), Gyre Therapeutics, Inc.'s EBITDA margin has grown at a -58.6% compound annual growth rate (CAGR), from -273.2% to 8%.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.